Notably, prior metabolomic analyses have identified diminished caffeine and caffeine-metabolite levels as biomarkers of increased PD vulnerability [7,25,37,38], with effects more pronounced in LRRK2-associated PD than in idiopathic cases [14,16,39]. The gene discussed is LRRK2; the disease is Parkinson disease.